Literature DB >> 33877638

Penetration of echinocandins into wound secretion of critically ill patients.

Tiziana Gasperetti1, René Welte1, Herbert Oberacher2, Jana Marx1, Ingo Lorenz3, Peter Schellongowski4, Thomas Staudinger4, Karin Burgmann4, Philipp Eller5, Tobias Santner6, Andrea Griesmacher6, Hartwig Pfisterer6, Stephan Eschertzhuber7,8, Maria Aigner9,10, Michael Joannidis11, Romuald Bellmann12.   

Abstract

PURPOSE: Wound infections caused by Candida are life-threatening and difficult to treat. Echinocandins are highly effective against Candida species and recommended for treatment of invasive candidiasis. As penetration of echinocandins into wounds is largely unknown, we measured the concentrations of the echinocandins anidulafungin (AFG), micafungin (MFG), and caspofungin (CAS) in wound secretion (WS) and in plasma of critically ill patients.
METHODS: We included critically ill adults with an indwelling wound drainage or undergoing vacuum-assisted closure therapy, who were treated with an echinocandin for suspected or proven invasive fungal infection. Concentrations were measured by liquid chromatography with UV (AFG and MFG) or tandem mass spectrometry detection (CAS).
RESULTS: Twenty-one patients were enrolled. From eight patients, serial WS samples and simultaneous plasma samples were obtained within a dosage interval. AFG concentrations in WS amounted to < 0.025-2.25 mg/L, MFG concentrations were 0.025-2.53 mg/L, and CAS achieved concentrations of 0.18-4.04 mg/L. Concentrations in WS were significantly lower than the simultaneous plasma concentrations and below the MIC values of some relevant pathogens.
CONCLUSION: Echinocandin penetration into WS displays a high inter-individual variability. In WS of some of the patients, concentrations may be sub-therapeutic. However, the relevance of sub-therapeutic concentrations is unknown as no correlation has been established between concentration data and clinical outcome. Nevertheless, in the absence of clinical outcome studies, our data do not support the use of echinocandins at standard doses for the treatment of fungal wound infections, but underline the pivotal role of surgical debridement.

Entities:  

Keywords:  Echinocandin antifungals; Invasive candidiasis; Target-site pharmacokinetics; Vacuum assisted closure therapy; Wound infection

Year:  2021        PMID: 33877638     DOI: 10.1007/s15010-021-01604-x

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  24 in total

1.  Micafungin at a standard dosage of 100 mg/day achieves adequate plasma exposure in critically ill patients with severe burn injuries.

Authors:  M J Asensio; M Sánchez; B Galván; E Herrero; L Cachafeiro; A Agrifoglio; E Perales; S Luque; A García-de-Lorenzo
Journal:  Intensive Care Med       Date:  2014-12-03       Impact factor: 17.440

2.  Treatment of Suspected Invasive Fungal Infection in War Wounds.

Authors:  Carlos J Rodriguez; David R Tribble; Debra L Malone; Clinton K Murray; Elliot M Jessie; Mansoor Khan; Mark E Fleming; Benjamin K Potter; Wade T Gordon; Stacy A Shackelford
Journal:  Mil Med       Date:  2018-09-01       Impact factor: 1.437

3.  Severe fungal infections following blunt traumatic injuries: A 5-year multicenter descriptive study.

Authors:  Constance McGraw; Matthew Carrick; Francie Ekengren; Gina Berg; Mark Lieser; Alessandro Orlando; Robert Madayag; Allen Tanner Ii; Michael Kelly; Kaysie Banton; David Bar-Or
Journal:  Injury       Date:  2019-10-14       Impact factor: 2.586

4.  Necrotizing Fasciitis due to Candida Infection after Thyroid Surgery.

Authors:  Mustafa Aslıer
Journal:  Turk Arch Otorhinolaryngol       Date:  2020-03-26

5.  Micafungin concentrations in the plasma and burn eschar of severely burned patients.

Authors:  Junichi Sasaki; Satoshi Yamanouchi; Daisuke Kudo; Tomoyuki Endo; Ryosuke Nomura; Kiyotsugu Takuma; Shigeki Kushimoto; Yotaro Shinozawa; Satoshi Kishino; Shingo Hori; Naoki Aikawa
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

6.  Distribution of micafungin in the tissue fluids of patients with invasive fungal infections.

Authors:  Noriaki Yamada; Keisuke Kumada; Satoshi Kishino; Nobuo Mochizuki; Keiko Ohno; Shinji Ogura
Journal:  J Infect Chemother       Date:  2011-05-03       Impact factor: 2.211

7.  Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid.

Authors:  Asma Lat; George R Thompson; Michael G Rinaldi; Sheryl A Dorsey; Gennethel Pennick; James S Lewis
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

8.  Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.

Authors:  A García-de-Lorenzo; S Luque; S Grau; A Agrifoglio; L Cachafeiro; E Herrero; M J Asensio; S M Sánchez; J A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

9.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

10.  Quantification of anidulafungin and micafungin in human body fluids by high performance-liquid chromatography with UV-detection.

Authors:  René Welte; Herbert Oberacher; Bernhard Schwärzler; Michael Joannidis; Romuald Bellmann
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2019-12-12       Impact factor: 3.205

View more
  1 in total

1.  Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis.

Authors:  Milo Gatti; Matteo Rinaldi; Giuseppe Ferraro; Alice Toschi; Natascia Caroccia; Federica Arbizzani; Emanuel Raschi; Elisabetta Poluzzi; Federico Pea; Pierluigi Viale; Maddalena Giannella
Journal:  Mycoses       Date:  2021-08-23       Impact factor: 4.931

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.